Colibri Heart Valve

Colibri Heart Valve is an emerging, pre-revenue medical device company developing a disruptive, ready-for-use TAVI system for aortic valve replacement. Its core innovation is a pre-mounted, pre-crimped valve utilizing dry tissue technology, which aims to reduce procedural complexity, improve quality control, and enable a lower delivery profile compared to incumbent systems. The company is in the clinical development stage, having initiated a feasibility study for its second-generation system in 2018, and is positioned to address significant operational inefficiencies in the rapidly growing transcatheter heart valve market.

Proprietary 'dry tissue' platform enabling pre-mounted, pre-crimped, ready-for-use transcatheter heart valves. Features a unique folded leaflet design from porcine pericardium and a low-profile (9Fr) balloon-expandable delivery system.

The TAVR market is dominated by large players like Edwards Lifesciences (Sapien family) and Medtronic (CoreValve/Evolut family), with Abbott (Portico) and others also competing. Colibri's primary differentiation is its pre-mounted, dry-tissue, ready-for-use design, which contrasts with the standard 'wet' systems requiring on-site preparation. It aims to compete on procedural ease and efficiency rather than direct clinical outcome claims at this stage.